GENETHERA INC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)

ITEM 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

GENETHERA, INC. AND CUSHMAN&WAKE FIELD ENTERED INTO A CONSULTING AGREEMENT

On September 9, 2021 GeneThera Inc. entered into a representation agreement with Cushman and Wakefield Us Inc. According to the terms on the agreement, Cushman and Wake field will represent GeneThera Inc in any transaction related to the acquisition of land in connection with to the construction of GeneThera's Biosafety Level 3 (BSL-3) laboratory facilities to be used as molecular robotic diagnostic therapeutic and research facilities for SARS-CoV-2 and other zoonotic diseases. Additionally Cushman & Wakefield will represent GeneThera in any transaction to secure warehouse space related to GeneThera assembly and storage of mobile laboratory units for the development of the wastewater surveillance network. Scope of the services and fees are outlined in Exhibit A attached to the Agreement. GeneThera Inc appoints Cushman & Wakefield as its sole agent and grants Cushman &Wakefield the exclusive right to represent GeneThera in any real estate transaction related to the Company Zoonotic Infectious Disease Alert Shield (ZIDAS) project.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

Exhibit    Description
Number

  10.1       Collaboration Agreement

104        Cover Page Interactive Data File (embedded within the Inline XBRL
           document)





2

© Edgar Online, source Glimpses